Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Lorenzo's Oil Treatment in X-linked Adrenoleukodystrophy

X 염색체 연관 부신백질이영양증에서 Lorenzo Oil의 투여효과

  • Kim, Hyo Jung (Department of Pediatrics, Kwangju Christian Hospital) ;
  • Kim, Eun Young (Department of Pediatrics, Kwangju Christian Hospital) ;
  • Woo, Young Jong (Department of Pediatrics Chonnam National University Medical School) ;
  • Kook, Hoon (Department of Pediatrics Chonnam National University Medical School)
  • 김효정 (광주기독병원 소아과) ;
  • 김은영 (광주기독병원 소아과) ;
  • 우영종 (전남대학교 의과대학 소아과학교실) ;
  • 국훈 (전남대학교 의과대학 소아과학교실)
  • Received : 2005.06.03
  • Accepted : 2005.08.01
  • Published : 2005.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Though more than 15 years have passed after introduction of Lorenzo's oil therapy in X-linked adrenoleukodystrophy(ALD), its efficacy is still fully not known. In patients who already have neurologic symptoms, most reports indicate that the neurologic disability continues to increase. We evaluated its efficacy in X-linked ALD patients. Methods : Four patients who were treated with Lorenzo's oil for at least 12 months were enrolled from 1996 to 2003. During treatment, changes of neurologic symptoms, brain magnetic resonance imaging(MRI) findings, and serum saturated very long-chain fatty acid(C26:0) were assessed. Results : Two patients with childhood cerebral ALD had progression of neurologic symptoms and MRI lesions during treatment. One asymptomatic patient developed childhood cerebral ALD after six year treatment of Lorenzo's oil. One "Addison only" patient remained neurologically intact after three years. During Lorenzo's oil therapy, serum C26:0 levels which had increased at diagnosis decreased in all four patients. Conclusion : Treatment with Lorenzo's oil did not prevent disease progression in childhood cerebral ALD patients who were already symptomatic. Long term follow up will be needed in asymptomatic ALD including "Addison only" to reveal the efficacy of Lorenzo's oil.

목 적 : X 염색체 연관 부신백질이영양증 환자에게 단일 불포화지방산의 혼합물인 Lorenzo oil을 투여하였더니 혈중 포화장쇄지방산치가 감소되었다는 보고가 1989년에 있은 이래, 부신백질이영양증을 가진 환자들의 많은 수가 Lorenzo oil을 복용해 왔다. 그러나 실제 투여효과에 대해서 아직까지 완전하게 알려진 바는 없고, 신경학적 증상이 있는 경우는 투여를 해도 진행을 막지 못하는 것으로 보고되었다. 본 저자들은 X 염색체 연관 부신백질이영양증 환아들에서 Lorenzo oil의 투여효과를 알아보고자 본 연구를 시행하였다. 방 법 : 1996년 1월부터 2003년 6월까지 광주기독병원과 전남대학교병원 소아과에서 부신백질이영양증으로 진단받고 추적 중인 환아들 중 Lorenzo oil을 적어도 1년 이상 경구 투여하였던 4명의 남아들(소아대뇌형으로 신경학적 증상이 있었던 2례, 신경학적 증상이 없었던 2례)을 대상으로 하였다. Lorenzo oil 투여 전후의 혈중 포화 장쇄지방산치(C26:0)의 변화, 신경학적 증상 및 뇌 자기공명영상 병변의 진행 등을 조사하였다. 소아대뇌형 2례의 경우는, 같은 시기에 소아대뇌형 ALD로 진단받고 Lorenzo oil을 투여하지 않았던 5례를 대조군으로 하여 임상경과의 진행을 비교하고자 하였다. 결 과 : 1) 소아 대뇌형으로 이미 신경학적 증상이 있었던 2례는 Lorenzo oil 투여 후에도 신경학적 증상과 뇌병변의 진행을 보였다. Lorenzo oil 비투여군과 비교시, 증례수가 적어 통계적 비교를 할 수는 없었지만, 투여군에서 신경학적 진행이 느린 것으로 생각되었다. 2) 신경학적 증상이 없는 상태에서 투여했던 2례 중 1례는 5년 후 소아대뇌형으로 진행하였고, 나머지 1례 "Addison only"는 증상 없이 3년째 추적관찰 중이다. 3) 4례 모두에서 진단 당시 증가되었던 포화 장쇄지방산치(C26:0)는 Lorenzo oil 투약 후 감소되어 3례에서는 정상화되었다. 4) Lorenzo oil 투여 중 2례에서 경한 혈소판 감소, 1례에서 경한 간기능치 상승 등의 부작용이 있었다. 결 론 : Lorenzo oil의 투여로 혈중 포화장쇄지방산치는 감소하였으나, 이미 신경학적 증상이 있는 소아 대뇌형의 경우는 임상경과의 진행을 막지 못하였다. 증상이 없는 경우, 투여효과를 판정하는데는 장기적인 추적관찰이 필요하리라 사료된다.

Keywords

References

  1. Moser HW, Smith KD, Watkins PA, Powers J, Moser AB. X-linked adrenoleukodystrophy. In : Scriver CR, Beaudet AL, editors. The metabolic & molecular bases of inherited disease. 8th ed. New York : McGraw-Hill company, 2001: 3257-301
  2. Moser HW, Fatemi A, Zackowski K, Smith S, Golay X, Muenz L, et al. Evaluation of therapy of X-linked adrenoleukodystrophy. Neurochem Res 2004;29:1003-16 https://doi.org/10.1023/B:NERE.0000021245.12181.90
  3. Rizzo WB, Leshner RT, Odone A, Damman AL, Craft DA, Jensone ME, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989;39:1415-22 https://doi.org/10.1212/WNL.39.11.1415
  4. Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:274-9 https://doi.org/10.1159/000112173
  5. Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J, et al. Adrenoleukodystrophy : phenotypic variability and implications for therapy. J Inher Metab Dis 1992;15:645-64 https://doi.org/10.1007/BF01799621
  6. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I, et al. A two-year trial of oleic acid and erucic acids('Lorenzo's oil') as treatment for adrenomyeloneuropathy. N Engl J Med 1993;329:745-52. https://doi.org/10.1056/NEJM199309093291101
  7. Asano J, Sujuki Y, Yajima S, Inoue K, Shimozawa N, Kondo N, et al. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev 1994;16:454-8 https://doi.org/10.1016/0387-7604(94)90007-8
  8. Korenke GC, Hunneman DH, Kohler J, StOckler S, Landmark K, Hanefeld F. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/ adrenomyeloneuropathy : effect on clinical, biochemical, and neurophysiological parameters. Eur J Pediatr 1995; 154:64-70 https://doi.org/10.1007/BF01972976
  9. Moser HW, Borel J. Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr 1995;15:379-97 https://doi.org/10.1146/annurev.nu.15.070195.002115
  10. Van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B Jr, Wanders RJ, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with 'Lorenzo's oil'. J Neurol Neurosurg Psychiat 1999;67: 290-9 https://doi.org/10.1136/jnnp.67.3.290
  11. Brown FR 3rd, van Duyn MA, Moser AB, Schulman JD, Rizzo WB, Snyder RD, et al. Adrenoleukodystrophy : effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J 1982;151: 164-72
  12. Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J. Adrenoleukodystrophy : oleic acid lowers fibroblast saturated C22-26 fatty acids. Neurology 1986;36:357- 61 https://doi.org/10.1212/WNL.36.3.357
  13. Rizzo WB, Phillips MW, Dammann AL, Leshner RT, Jennings SS, Avigan J, et al. Adrenoleukodystrophy : dietary oleic acid lowers hexacosanoate levels. Ann Neurol 1987;21: 232-9 https://doi.org/10.1002/ana.410210304
  14. Odone A, Odone M. Lorenzo's oil : a new treatment for adrenoleukodystrophy. J Pediatr Neurosci 1989;5:55-61 https://doi.org/10.4103/1817-1745.66681
  15. Moser HW. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995;54:740-5 https://doi.org/10.1097/00005072-199509000-00017
  16. Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleu-kodystrophy brain after treatment with Lorenzo's oil. Ann Neurol 1994;36:741-6. https://doi.org/10.1002/ana.410360509
  17. Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adrenoleukodystrophy : cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992;51:630-43 https://doi.org/10.1097/00005072-199211000-00007
  18. Bourre JM, Daudu O, Baumann N. Nervonic acid biosynthesis by erucyl-coA elongation in normal and quaking mouse brain microsomes. Elongation of other unsaturated fatty acyl-coAs(mono and polyunsaturated). Biochim Biophys Acta 1976;424:1-7 https://doi.org/10.1016/0005-2760(76)90043-6
  19. Janet B, Jannifer C. ALD-AMN diet cookbook. Sycamore : United Leukodystrophy Foundation, 1990:1-20
  20. Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990;322:1860-6 https://doi.org/10.1056/NEJM199006283222607
  21. Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999;12:167-76 https://doi.org/10.1097/00019052-199904000-00007
  22. Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M, et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000;356:713-8 https://doi.org/10.1016/S0140-6736(00)02629-5
  23. Singh I, Pahan K, Kahn M. Lovastatin and sodium phenylacetate normalize the levels of very-long-chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett 1998;426:342-6 https://doi.org/10.1016/S0014-5793(98)00370-6
  24. Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999;269:71-4 https://doi.org/10.1016/S0304-3940(99)00414-0
  25. Weinhofer I, Forss-Petter S, Zigman M, Berger J. Cholesterol regulates ABCD2 expression : implications for the therapy of X-linked adrenoleukodystrophy. Hum Mol Genet 2002;11:2701-8 https://doi.org/10.1093/hmg/11.22.2701
  26. Koc ON, Day J, Nieder M, Gerson SL, Luzarus HM, Krivit W. Allogenic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy(MLD) and Hurler syndrome( MPS-IH). Bone Marrow Transplant 2002;30:215-22. https://doi.org/10.1038/sj.bmt.1703650